

**Table 1 Baseline characteristics of the study sample: patients aged ≥ 18 years with T2DM who were starting second-line glucose-lowering therapy, Lebanon, 2015–2019**

Parameter	Patients (n = 348)	
	No.	%
<b>Sex, male</b>	198	56.9
Main working status		
Employed/self-employed	132	52.3
Not working	139	40.0
Retired	12	3.4
Missing data	15	4.3
<b>Health insurance coverage</b>		
Private	129	37.1
Public/governmental	84	24.1
Mixed	39	11.2
No insurance	73	21.0
Missing data	23	6.6
<b>Education level (years)</b>		
No formal education	30	8.6
Primary (1–6)	67	19.3
Secondary (7–13)	146	42.0
University/higher education (13+)	74	21.3
Missing data	31	8.9
<b>Tobacco smoking</b>		
Non-smoker	210	60.3
Ex-smoker	43	6.8
Current smoker	91	26.2
Missing data	23	6.6
<b>Alcohol drinking</b>		
Lifetime abstainer	273	79.4
Former drinker	2	0.6
Drinker	69	20.1
Missing data	4	1.2
<b>Hypertension</b>	157	45.1
<b>Hyperlipidaemia</b>	169	48.6
<b>Any microvascular complication</b>	49	14.1
<b>Any macrovascular complication</b>	43	12.1
	Mean	SD
<b>Age (years)</b>	59.2	10.3
<b>HbA1c (%)</b>	8.5	1.6
<b>Fasting glucose (mg/dL)</b>	178.7	56.5
<b>Duration of diabetes (years)</b>	6.7	6.5
<b>Body mass index (kg/m<sup>2</sup>)</b>	29.8	4.6
<b>Systolic blood pressure (mmHg)</b>	133.0	14.4
<b>Diastolic blood pressure (mmHg)</b>	77.5	8.1
<b>Low-density lipoprotein cholesterol (mg/dL)</b>	109.2	38.6